| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
6ß4 Integrin Maintains the Survival of Human Breast Carcinoma Cells In vivo
Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
Requests for reprints: Arthur M. Mercurio, Department of Cancer Biology, University of Massachusetts Medical School, LRB-408, 364 Plantation Street, Worcester, MA 01605. Phone: 508-856-8676; Fax: 508-856-1310; E-mail: arthur.mercurio{at}umassmed.edu.
The
6ß4 integrin has been widely implicated in carcinoma function in vitro; however, in vivo data are scarce. To determine the importance of
6ß4 in tumor progression, a SUM-159 breast carcinoma cell line that is essentially devoid of
6ß4 expression was generated using an RNA interference strategy. Loss of
6ß4 expression inhibits colony formation in soft agar assays, suggesting a vital role for
6ß4 in survival signaling and anchorage-independent growth. Orthotopic injection of the ß4-deficient cell line into the mammary fat pad of immunocompromised mice yielded significantly fewer and smaller tumors than the control cell line, revealing a role for the
6ß4 integrin in tumor formation. Under conditions that mimicked the in vivo environment, decreased expression of the
6ß4 integrin led to enhanced apoptosis as determined by the percentage of Annexin V-FITC+, PI cells and the presence of caspase-3 cleavage products. Recombinant vascular endothelial growth factor (VEGF) significantly inhibited the cell death observed in the ß4-deficient cell line, demonstrating the importance of VEGF expression in this survival pathway. Furthermore, loss of
6ß4 expression leads to enhanced apoptosis and reduced expression of VEGF in breast carcinoma cells in vivo. Importantly, the specificity of
6ß4 in both the in vitro and in vivo assays showed that reexpression of the ß4 subunit into the ß4-deficient cell line could rescue the functional phenotype. Taken together, these data implicate the
6ß4 integrin in tumor formation by regulating tumor cell survival in a VEGF-dependent manner.
This article has been cited by other articles:
![]() |
S. Lu, K. Simin, A. Khan, and A. M. Mercurio Analysis of Integrin {beta}4 Expression in Human Breast Cancer: Association with Basal-like Tumors and Prognostic Significance Clin. Cancer Res., February 15, 2008; 14(4): 1050 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Friedland, J. N. Lakins, M. G. Kazanietz, J. Chernoff, D. Boettiger, and V. M. Weaver {alpha}6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-{kappa}B-dependent resistance to apoptosis in 3D mammary acini J. Cell Sci., October 15, 2007; 120(20): 3700 - 3712. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Merdek, X. Yang, C. A. Taglienti, L. M. Shaw, and A. M. Mercurio Intrinsic Signaling Functions of the beta4 Integrin Intracellular Domain J. Biol. Chem., October 12, 2007; 282(41): 30322 - 30330. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Folgiero, R. E. Bachelder, G. Bon, A. Sacchi, R. Falcioni, and A. M. Mercurio The {alpha}6{beta}4 Integrin Can Regulate ErbB-3 Expression: Implications for {alpha}6{beta}4 Signaling and Function Cancer Res., February 15, 2007; 67(4): 1645 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bertotti, P. M. Comoglio, and L. Trusolino {beta}4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth J. Cell Biol., December 18, 2006; 175(6): 993 - 1003. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bon, V. Folgiero, G. Bossi, L. Felicioni, A. Marchetti, A. Sacchi, and R. Falcioni Loss of {beta}4 Integrin Subunit Reduces the Tumorigenicity of MCF7 Mammary Cells and Causes Apoptosis upon Hormone Deprivation. Clin. Cancer Res., June 1, 2006; 12(11): 3280 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wilhelmsen, S. H.M. Litjens, and A. Sonnenberg Multiple Functions of the Integrin {alpha}6{beta}4 in Epidermal Homeostasis and Tumorigenesis Mol. Cell. Biol., April 15, 2006; 26(8): 2877 - 2886. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |